Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Information Technology Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Vanguard Information Technology Index Fund ETF trades at $115.39. Which is the better fit depends on your goals.
| ACAD | VGT | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $125.77 |
52-Week Low | $20.06 | $83.59 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
The Vanguard Information Technology ETF (VGT) trades at $116.37, up 1.51% on the day, with technical indicators showing a mixed but slightly bullish bias. The fund recently executed an 8-for-1 stock split and maintains a low 0.09% expense ratio, positioning it as a cost-efficient vehicle for broad tech exposure. Financial media sentiment is generally positive, highlighting VGT's strong long-term track record and diversification benefits compared to more concentrated tech ETFs.
The outlook for VGT is tied to the broader technology sector's performance, particularly hyperscaler capital expenditure and semiconductor cycles. Key opportunities include exposure to AI-driven growth through a diversified portfolio. Primary risks involve sector concentration, market volatility, and potential valuation pressures if tech earnings growth decelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
